文献速递冠心病

老年非ST段抬高型心肌梗死侵入性治疗策略选择与实施的最新证据

Updated evidence on selection and implementation of an invasive treatment strategy for older patients with non-ST-segment elevation myocardial infarction.
PubMed 文献 · Heart · 2025-05-23

本文综述老年NSTEMI患者侵入性治疗策略的最新证据。英国每年约2万例≥75岁NSTEMI患者,其预后较年轻患者差。ESC指南建议整体评估侵入性治疗而无年龄切点,但老年患者因证据不足较少接受侵入性治疗。SENIOR-RITA试验显示侵入性治疗安全,减少非致死性心梗和后续血运重建,但不改善死亡率。个体化风险评估和共享决策至关重要。

要点

  • 老年NSTEMI患者预后较年轻患者差,需 robust 证据指导治疗。
  • SENIOR-RITA试验:侵入性治疗安全,减少非致死性心梗和血运重建,不改善死亡率。
  • 约30%老年NSTEMI患者衰弱,约65%认知障碍,多数合并至少两种共病,影响风险。

核心结论

  • SENIOR-RITA试验表明老年NSTEMI患者侵入性管理安全,减少非致死性心肌梗死和后续血运重建,但未改善死亡率。
  • 个体化风险评估和共享决策对老年NSTEMI侵入性治疗决策至关重要。

研究设计与样本

  • 综述,讨论老年NSTEMI患者侵入性管理的最新证据,包括老年综合征对临床结局的影响。

主要发现

  • 老年NSTEMI患者住院和长期结局较年轻患者差。
  • 约30%老年NSTEMI患者衰弱,约65%认知障碍,多数至少合并两种额外共病。
  • SENIOR-RITA试验显示侵入性管理减少非致死性心肌梗死和后续血运重建,未改善死亡率。

关键数值与推荐

  • ESC指南推荐侵入性管理应整体考虑,无指定年龄切点。
  • SENIOR-RITA试验:侵入性管理在老年NSTEMI患者中安全,减少非致死性心肌梗死和后续血运重建,不改善死亡率。

临床怎么用

  • 对老年NSTEMI患者应进行个体化风险评估,考虑衰弱、认知障碍和共病。
  • 与患者共享决策,权衡侵入性治疗的风险与获益。

局限性

  • 老年患者代表性试验证据匮乏,招募符合临床实际的老年患者极具挑战。
  • chronological age 不能反映老年人群异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-ST-segment elevation myocardial infarction (NSTEMI) is the most common acute coronary syndrome diagnosis in older patients. In the UK, there are ~20 000 NSTEMI cases annually in patients aged ≥75 years. Despite therapeutic advances in pharmacological and invasive management, studies show that older patients with NSTEMI experience worse in-hospital and long-term outcomes than younger patients, suggesting a clear need for robust evidence in this cohort.The European Society of Cardiology guidelines recommend that invasive management should be considered holistically with no specified age cut-offs. However, older patients are less likely to receive invasive management due to a paucity of evidence from trials that represent contemporary clinical characteristics of older adults. Recruiting older patients realistic of those encountered in clinical practice is hugely challenging. Chronological age alone does not reflect the heterogeneity of the older population; ~30% of older patients with NSTEMI are frail, ~65% are cognitively impaired and most live with at least two additional comorbidities that can influence risk. Weighing the risk of an NSTEMI in an older adult against competing risks attributable to underlying frailty, comorbidities and cognitive impairment poses a key challenge.Recently, the SENIOR-RITA trial showed that invasive management in older patients with NSTEMI is safe and reduces non-fatal myocardial infarction and subsequent revascularisation but does not improve mortality. Individualised risk assessment and shared decision-making is necessary to guide these nuanced decisions. This review discusses the latest evidence regarding invasive management in the older population with NSTEMI, including the impact of geriatric syndromes on clinical outcomes.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Gill, Kunadian. Updated evidence on selection and implementation of an invasive treatment strategy for older patients with non-ST-segment elevation myocardial infarction. Heart. 2025. PMID: 39938941. doi:10.1136/heartjnl-2024-325157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。